‘CIBA EHP Cura I’ technology addresses Enterocytozoon hepatopenaei a microsporidian pathogen that poses a severe threat to the global shrimp industry.
ICAR-Central Institute of Brackishwater Aquaculture, Chennai, signed a Memorandum of Understanding with M/s Neomeds, Hyderabad, Telangana for the technology transfer of ‘CIBA EHP Cura I’- technology. This innovative technology addresses Enterocytozoon hepatopenaei a microsporidian pathogen that poses a severe threat to the global shrimp industry. After 6-7 years of exclusive research on EHP, ICAR-CIBA developed ‘CIBA EHP cura I’ a treatment that was field validated and led to its commercialization.
Dr. Kuldeep K. Lal, Director, ICAR-CIBA highlighted the severity of EHP pathogen in shrimp aquaculture and the significance of ‘CIBA EHP cura I’ in combating the issue and opined that it will help the farming community in India.
Dr. T. Sathish Kumar, Scientist, and Principal Investigator, ‘CIBA EHP cura I’, briefed about the genesis of development and significance of this product in the treatment and control of EHP and informed the association with M/s Neomeds.
